(Q27006890)

A Cheng

series ordinal

2

1 reference

PJ Sambrook

series ordinal

3

1 reference

AN Goss

series ordinal

4

1 reference

language of work or name

1 reference

September 2014

1 reference

Australian Dental Journal

published in

1 reference

volume

59

1 reference

page(s)

296-301; quiz 401

1 reference

issue

3

1 reference

A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement

cites work

1 reference

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

21 January 2018

1 reference

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

21 January 2018

1 reference

Structure-based design of novel potent nonpeptide thrombin inhibitors

21 January 2018

1 reference

Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor.

21 January 2018

1 reference

Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery

21 January 2018

1 reference

Trials and tribulations of non-inferiority: the ximelagatran experience

21 January 2018

1 reference

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

21 January 2018

1 reference

Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study

21 January 2018

1 reference

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

21 January 2018

1 reference

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

21 January 2018

1 reference

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

21 January 2018

1 reference

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

21 January 2018

1 reference

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

21 January 2018

1 reference

Current concepts of the management of dental extractions for patients taking warfarin

21 January 2018

1 reference

Thrombin inhibitors: surgical considerations and pharmacology

21 January 2018

1 reference

Safe use of hemodialysis for dabigatran removal before cardiac surgery

21 January 2018

1 reference

Platelet activity of high-dose factor VIIa is independent of tissue factor

21 January 2018

1 reference